Supporting Information

Absorption characteristic of paeoniflorin-6'-O-benzene sulfonate(CP-25) in *in situ* single-pass intestinal perfusion in rats

Xiao-Dan Yang¹, Chun Wang¹, Peng Zhou, Jun Yu,

James Asenso, Yong Ma*, Wei Wei*

*Institute of Clinical Pharmacology, Anhui Medical University,
Key Laboratory of Anti-inflammatory and Immune Medicine,
Ministry of Education, Anhui Collaborative Innovation Center of
Anti-inflammatory and Immune Medicine, Hefei 230032, China*

Correspondence to:

Yong Ma (Telephone: 86-551-6516-1209; Fax: 86-551-6516-1209; E-mail address:
my4973766@163.com)

Wei Wei (Telephone: 86-551-6516-1209; Fax: 86-551-6516-1209; E-mail address:
wwei@ahmu.edu.cn)

Xiao-Dan Yang, Chun Wang contributed equally to this work.

table 1s. Standard curve of CP-25 in mobile phase ($\bar{x} \pm s$, n=5)

Concentration ($\mu\text{g}\cdot\text{mL}^{-1}$)	Peak area					$\bar{x} \pm s$	RSD
1	13.6	13.9	12.7	13.5	13.3	13.4 ± 0.45	3.34%
2	24.8	25.5	24.2	24.6	23.4	24.5 ± 0.77	2.16%
5	58.6	57.4	56.8	59	56.2	57.6 ± 1.18	2.05%
10	115	117.7	116.6	117.1	119.6	117.2 ± 1.67	1.43%
20	230.3	241.7	251.9	243.5	239.1	241.3 ± 7.80	2.2%
40	499.5	470.9	463	470.4	476.2	476 ± 13.95	3.6%

table 2s. Standard curve of Pae in mobile phase ($\bar{x} \pm s$, n=5)

Concentration ($\mu\text{g}\cdot\text{mL}^{-1}$)	Peak area					$\bar{x} \pm s$	RSD
1	13.6	13.9	12.9	13.2	13.9	13.5 ± 0.44	3.27%
2	27	29	26.9	28.2	28.4	27.9 ± 0.92	3.29%
5	68.8	68.9	66.6	66.8	67.9	67.8 ± 1.08	1.59%
10	138.8	141	137.4	135.2	139.1	138.3 ± 2.16	1.56%
20	279.9	276.8	266.1	261.4	291.3	275.1 ± 11.80	4.29%
40	569.2	566.9	541.8	534.7	561.9	554.9 ± 15.63	2.82%

figure1s. Standard curves of CP-25 and Pae in mobile phase ($\bar{x} \pm s$, n=4)

table 3s. Relative recoveries of Pae and CP-25 in the blank intestinal

circulating solution($\bar{x} \pm s$, n=3)

	Concentration		Peak area					Recoveries
	($\mu\text{g}\cdot\text{mL}^{-1}$)	Control group			Sample group			
CP-25	5	58.6	57.4	56.8	53.2	52.0	55	92.71%
	10	115	117.7	116.6	116.7	117.3	118.1	100.80%
	20	230.3	241.7	251.9	216.3	219.2	218	90.27%
Pae	5	68.8	68.9	66.6	62.7	64.4	62.1	92.61%
	10	138.8	141	137.4	141.9	139.0	133.9	99.42%
	20	279.9	276.8	266.1	270.7	273.3	276.5	99.72%

table 4s. Precision of Pae and CP-25 in the perfusion solution ($\bar{x} \pm s$, n=3)

	Concentration ($\mu\text{g}\cdot\text{ml}^{-1}$)	Intra-day					Inter-day				
		Peak area			RSD		Peak area			RSD	
Pae	5	61.7	68.0	67.9	5.48%	55.27	56.17	54.90	55.40	55.43	0.83%
	10	139.5	137.9	138.6	0.58%	112.83	108.73	108.27	113.13	114.03	2.41%
	20	280.1	283.6	287.4	1.29%	223.53	224.0	217.83	221.57	224.30	1.21%
CP-25	5	55.9	55.4	54.5	1.30%	65.87	68.77	71.27	69.00	67.83	2.86%
	10	112.9	113.9	111.7	0.99%	138.67	138.63	138.93	136.83	139.40	0.71%
	20	218.7	226.3	225.6	1.86%	283.70	287.90	280.63	283.13	285.20	0.94%

table 5s. Stability of CP-25 and Pae in the blank intestinal circulating solution ($\bar{x} \pm s$, n=4)

	CP-25	Pae
0(h)	107.67	146.40
0.5(h) at 37°C	106.97	142.37
1(h) at 37°C	106.43	140.60
2(h) at 37°C	103.90	141.73
3(h) at 37°C	103.27	140.80
RSD (%)	1.84%	1.66%